Measuring Atomoxetine and Aroxybutinin In Patients With OSA
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study of
AD109 in participants with OSA. Enrolled participants will be randomized to one of 5 parallel
treatment arms.